The results obtained by double agent treatment in vivo in xenografts suggests a combination effect by EZH2i/FGFRi treatment and aligns with our in vitro findings of increased sensitivity against Bap1-deficient mesothelioma tumor cells. The gene discussed is BAP1; the disease is mesothelioma.